Vinci Pharmaceuticals Raises $8M Series A for Drug Delivery Platform
Vinci Pharmaceuticals has closed a Series A round topping $8 million, bringing total funding to more than $16.5 million to advance its EPIPLANT technology.
Vinci Pharmaceuticals Inc. has closed a Series A financing round exceeding $8 million aimed at advancing the company's proprietary EPIPLANT™ drug delivery platform, the company announced. The latest capital raise brings total funding secured by the firm to more than $16.5 million when combined with an earlier seed round of $8.5 million.
The back-to-back funding rounds signal sustained investor confidence in Vinci's EPIPLANT™ technology, which is designed as a specialized drug delivery mechanism. While specific therapeutic targets and clinical timelines were not disclosed in the announcement, the accumulated capital is intended to support the company's ongoing research and operational activities.
Read more Jonah Unveils Affordable Housing Marketing Tool for Multifamily Sector →
The Series A milestone marks a significant step for Vinci Pharmaceuticals as it works to move its platform technology further along the development pipeline. Companies at this stage typically use Series A funding to expand preclinical work, build out scientific teams, and prepare for regulatory milestones, though the company has not publicly outlined a specific use-of-proceeds breakdown.
The pharmaceutical drug delivery sector has attracted steady venture investment in recent years as developers seek more targeted and efficient mechanisms to administer therapeutics. Vinci's back-to-back rounds totaling more than $16.5 million position the company to compete in that landscape, pending further clinical and regulatory progress.
Continue reading at Banking & Financial Services.
